Document ID: FDA-2014-N-1051-0941
Agency: fda
Document Type: Notice
Title: Modified Risk Tobacco Product Application: Renewal Applications for
General Snus Smokeless Tobacco Products Submitted by Swedish Match U.S.A., Inc.
Posted Date: 2023-12-01T05:00Z

[Federal Register Volume 88, Number 230 (Friday, December 1, 2023)]
[Notices]
[Pages 83948-83949]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26498]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-1051]

Modified Risk Tobacco Product Application: Renewal Applications 
for General Snus Smokeless Tobacco Products Submitted by Swedish Match 
U.S.A., Inc.

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
an opportunity to provide public comment on modified risk tobacco 
product applications (MRTPAs). The applications are for renewal of 
existing modified risk tobacco product (MRTP) orders for General Snus 
smokeless tobacco products submitted by Swedish Match U.S.A., Inc.

DATES: Electronic or written comments on the application may be 
submitted beginning December 1, 2023. FDA will establish a closing date 
for the comment period as described in section I.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2014-N-1051 for ``Modified Risk Tobacco Product Applications: 
Renewal applications for General Snus smokeless tobacco products 
submitted by Swedish Match U.S.A., Inc.'' Received comments will be 
placed in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at https://www.regulations.gov or at 
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through 
Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read the background documents 
or electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the

[[Page 83949]]

``Search'' box and follow the prompts and/or go to the Dockets 
Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 
240-402-7500.

FOR FURTHER INFORMATION CONTACT: Dhanya John or Adrian Mixon, Office of 
Regulations, Center for Tobacco Products, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 71, Rm. G335, Silver Spring, MD 20993-
0002, 1-877-287-1373, email: [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    Section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) 
(21 U.S.C. 387k) addresses the marketing and distribution of MRTPs. 
MRTPs are tobacco products that are sold or distributed for use to 
reduce harm or the risk of tobacco-related disease associated with 
commercially marketed tobacco products. Section 911(a) of the FD&C Act 
prohibits the introduction or delivery for introduction into interstate 
commerce of any MRTP unless an order issued by FDA pursuant to section 
911(g) of the FD&C Act is effective with respect to such product.
    Section 911(d) of the FD&C Act describes the information that must 
be included in a MRTPA, which must be filed and evaluated by FDA before 
an applicant can receive an order from FDA. FDA is required by section 
911(e) of the FD&C Act to make a MRTPA available to the public (except 
for matters in the application that are trade secrets or otherwise 
confidential commercial information) and to request comments by 
interested persons on the information contained in the application and 
on the label, labeling, and advertising accompanying the application. 
The determination of whether an order is appropriate under section 911 
of the FD&C Act is based on the scientific information submitted by the 
applicant as well as the scientific evidence and other information that 
is made available to the Agency, including through public comments.
    Section 911(g) of the FD&C Act describes the demonstrations 
applicants must make to obtain an order from FDA under either section 
911(g)(1) or (g)(2). The applicant, Swedish Match U.S.A., Inc., is 
seeking a renewal of the order under section 911(g)(1) of the FD&C Act.
    FDA may issue an order under Section 911(g)(1) of the FD&C Act, if 
FDA has determined that the applicant has demonstrated that the 
proposed MRTP, as it is actually used by consumers, will:
     Significantly reduce harm and the risk of tobacco-related 
disease to individual tobacco users; and
     Benefit the health of the population as a whole taking 
into account both users of tobacco products and persons who do not 
currently use tobacco products.
    Section 911(g)(4) of the FD&C Act describes factors that FDA must 
take into account in evaluating whether a tobacco product benefits the 
health of individuals and the population as a whole.
    FDA is issuing this notice to inform the public that renewal MRTPAs 
submitted by Swedish Match U.S.A. Inc. for the following products 
(identified by FDA Submission Tracking Numbers (STN) (MR0000256.PD1--
MR0000256.PD9)) have been filed and are being made available for public 
comment:

 MR0000256.PD1: General Loose
 MR0000256.PD2: General Dry Mint Portion Original Mini
 MR0000256.PD3: General Portion Original Large
 MR0000256.PD4: General Classic Blend Portion White Large-12 ct
 MR0000256.PD5: General Mint Portion White Large
 MR0000256.PD7: General Nordic Mint Portion White Large- 12 ct
 MR0000256.PD8: General Portion White Large
 MR0000256.PD9: General Wintergreen Portion White Large

    The applicant is seeking renewal of the authorization to market 
General Loose, General Dry Mint Portion Original Mini, General Portion 
Original Large, General Classic Blend Portion White Large--12ct, 
General Mint Portion White Large, General Nordic Mint Portion White 
Large--12ct, General Portion White Large, and General Wintergreen 
Portion White Large Smokeless Tobacco Products (category)/Loose Snus 
and Portioned Snus (subcategories) as MRTPs under section 911(g)(1) of 
the FD&C Act.\1\ These products previously received such authorization 
in October 2019, and the applicant is including information from the 
previous MRTPAs by cross-reference.
---------------------------------------------------------------------------

    \1\ The notice of availability for the General Snus MRTPAs that 
received a modified risk granted order appeared in the Federal 
Register on August 27, 2014 (79 FR 51183) and the docket containing 
notices and public comments, FDA-2014-N-1051, is accessible at: 
https://www.regulations.gov/.
---------------------------------------------------------------------------

    FDA will post the application documents, including any amendments, 
to its website for the MRTPAs (see section II) for public comment on a 
rolling basis as they are redacted in accordance with applicable laws. 
In this document, FDA is announcing the availability of the first batch 
of application documents for public comment. FDA intends to establish a 
closing date for the comment period that is both at least 180 days 
after the date of this notice and at least 30 days after the final 
documents from the application are made available for public comment. 
FDA will announce the closing date at least 30 days in advance. FDA 
believes that this comment period is appropriate given the volume and 
complexity of the applications being posted.
    FDA will notify the public about the availability of additional 
application documents and comment period closing date via the Agency's 
web page for the MRTPAs (see section II) and by other means of public 
communication, such as by email to individuals who have signed up to 
receive email alerts. To receive email alerts, visit FDA's email 
subscription service management website (https://www.fda.gov/about-fda/contact-fda/get-email-updates), provide an email address, scroll down 
to the ``Tobacco'' heading, select ``Modified Risk Tobacco Product 
Application Update'', and click ``Submit''. To encourage public 
participation consistent with section 911(e) of the FD&C Act, FDA is 
making the redacted MRTPAs that are the subject of this notice 
available electronically (see section II).

II. Electronic Access

    Persons with access to the internet may obtain the document(s) at 
https://www.fda.gov/tobacco-products/advertising-and-promotion/swedish-match-usa-inc-mrtp-applications.

    Dated: November 28, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-26498 Filed 11-30-23; 8:45 am]
BILLING CODE 4164-01-P